X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
electricity (122) 122
basic electric elements (88) 88
electric solid state devices not otherwise provided for (88) 88
semiconductor devices (88) 88
general tagging of cross-sectional technologies spanning over several sections of the ipc (87) 87
general tagging of new technological developments (87) 87
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (87) 87
technologies or applications for mitigation or adaptation againstclimate change (87) 87
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (86) 86
humans (77) 77
index medicus (73) 73
male (71) 71
female (68) 68
aged (64) 64
middle aged (63) 63
oncology (62) 62
chemotherapy (48) 48
adult (47) 47
cancer (45) 45
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
electric communication technique (33) 33
metastasis (31) 31
colorectal cancer (28) 28
treatment outcome (27) 27
medicine & public health (26) 26
stomach cancer (26) 26
care and treatment (25) 25
cancer research (24) 24
colorectal neoplasms - drug therapy (24) 24
gastric cancer (24) 24
stomach neoplasms - drug therapy (24) 24
amusements (23) 23
card, board, or roulette games (23) 23
games (23) 23
games not otherwise provided for (23) 23
human necessities (23) 23
indoor games using small moving playing bodies (23) 23
physics (23) 23
sports (23) 23
video games (23) 23
wireless communications networks (23) 23
aged, 80 and over (22) 22
disease-free survival (22) 22
gastroenterology & hepatology (21) 21
research (21) 21
oxaliplatin (20) 20
analysis (19) 19
fluorouracil (19) 19
stomach neoplasms - pathology (19) 19
survival (19) 19
antimitotic agents (18) 18
antineoplastic agents (18) 18
camptothecin - analogs & derivatives (18) 18
drug combinations (18) 18
surgical oncology (18) 18
survival rate (18) 18
calculating (17) 17
cisplatin (17) 17
clinical trials (17) 17
computing (17) 17
counting (17) 17
electric digital data processing (17) 17
layered products (17) 17
layered products, i.e. products built-up of strata of flat ornon-flat, e.g. cellular or honeycomb, form (17) 17
performing operations (17) 17
telephonic communication (17) 17
transporting (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
gastroenterology (16) 16
tegafur - administration & dosage (16) 16
fluorouracil - administration & dosage (15) 15
leucovorin - administration & dosage (15) 15
neoplasm staging (15) 15
oncology, experimental (15) 15
trial (15) 15
oxonic acid - administration & dosage (14) 14
patients (14) 14
prognosis (14) 14
abdominal surgery (13) 13
adenocarcinoma - drug therapy (13) 13
bevacizumab (13) 13
cancer patients (13) 13
irinotecan (13) 13
kaplan-meier estimate (13) 13
leucovorin (13) 13
organoplatinum compounds - administration & dosage (13) 13
1st-line therapy (12) 12
camptothecin - administration & dosage (12) 12
capecitabine (12) 12
cisplatin - administration & dosage (12) 12
colorectal neoplasms - mortality (12) 12
colorectal neoplasms - pathology (12) 12
japan (12) 12
leucovorin - adverse effects (12) 12
measuring (12) 12
retrospective studies (12) 12
testing (12) 12
1st-line treatment (11) 11
double-blind (11) 11
metastases (11) 11
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (328) 328
French (43) 43
Japanese (37) 37
German (25) 25
Chinese (20) 20
Korean (7) 7
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma (NEC) of the digestive system. Clinical data from 258 patients with... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 853 - 860
Summary Background Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line... 
Hematology, Oncology and Palliative Medicine | TRIAL | CAPECITABINE | 1ST-LINE TREATMENT | INFUSIONAL FLUOROURACIL/LEUCOVORIN | THERAPY | ONCOLOGY | 5-FLUOROURACIL/FOLINIC ACID | FLUOROPYRIMIDINES | OXALIPLATIN | III NONINFERIORITY | FAILURE | Prodrugs - administration & dosage | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Fluorouracil - analogs & derivatives | Tegafur - adverse effects | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Adenocarcinoma - drug therapy | Oxonic Acid - adverse effects | Disease-Free Survival | Prodrugs - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Drug Combinations | Adenocarcinoma - mortality | Medical colleges | Chemotherapy | Oncology, Experimental | Colorectal cancer | Leucovorin | Research | Metastasis | Cancer | Fluorouracil | Analysis
Journal Article
Cancer Science, ISSN 1347-9032, 07/2014, Volume 105, Issue 7, pp. 812 - 817
This multicenter phase II study first investigated the efficacy and safety of nanoparticle albumin‐bound paclitaxel (nab‐paclitaxel) when given every 3 weeks... 
phase II | triweekly | Gastric cancer | nab‐paclitaxel | second‐line chemotherapy | Second-line chemotherapy | nab-paclitaxel | Phase II | Triweekly | PLUS CISPLATIN | CREMOPHOR-FREE | second-line chemotherapy | ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE | SALVAGE CHEMOTHERAPY | SUPPORTIVE CARE | ONCOLOGY | COMPARING IRINOTECAN | COMBINATION CHEMOTHERAPY | 1ST-LINE THERAPY | SOLVENT-BASED PACLITAXEL | Humans | Middle Aged | Kaplan-Meier Estimate | Neoplasm Recurrence, Local - drug therapy | Paclitaxel - adverse effects | Male | Stomach Neoplasms - pathology | Treatment Outcome | Stomach Neoplasms - drug therapy | Paclitaxel - therapeutic use | Albumins - therapeutic use | Disease-Free Survival | Antineoplastic Agents, Phytogenic - administration & dosage | Albumins - adverse effects | Leukopenia - chemically induced | Adult | Female | Aged | Antineoplastic Agents, Phytogenic - therapeutic use | Neutropenia - chemically induced | Stomach Neoplasms - mortality | Antineoplastic Agents, Phytogenic - adverse effects | Antimitotic agents | Relapse | Chemotherapy | Clinical trials | Albumin | Product development | Antineoplastic agents | Stomach cancer | Diseases | Cancer | Breast cancer | Metastasis | Neuropathy | Cancer therapies | Disease control | Survival | Blood | Nanoparticles | Lymphopenia | Paclitaxel | Drug dosages | Neutropenia | Pharmaceuticals | Index Medicus | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4438 - 4444
Journal Article
Gastric Cancer, ISSN 1436-3291, 1/2016, Volume 19, Issue 1, pp. 183 - 191
This study was conducted to investigate whether human epidermal growth factor receptor 2 (HER2) status, epidermal growth factor receptor (EGFR) status, and... 
Gastroesophageal junction cancer | Medicine & Public Health | Human epidermal growth factor receptor 2 | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | c-MET | Surgical Oncology | Gastric cancer | Epidermal growth factor receptor | 1ST-LINE TREATMENT | CLINICAL-FEATURES | LABEL PHASE-3 TRIAL | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | DOUBLE-BLIND | CARCINOMAS | ESOPHAGOGASTRIC JUNCTION | GASTROENTEROLOGY & HEPATOLOGY | GENE COPY NUMBER | EXPRESSION | Proto-Oncogene Proteins c-met - metabolism | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Receptor, ErbB-2 - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Receptor, Epidermal Growth Factor - metabolism | Biomarkers, Tumor - metabolism | Esophageal Neoplasms - mortality | Female | Adenocarcinoma - genetics | Retrospective Studies | Stomach Neoplasms - genetics | Esophagogastric Junction - pathology | Oxonic Acid - administration & dosage | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tegafur - administration & dosage | Aged | Biomarkers, Tumor - genetics | Stomach Neoplasms - mortality | Drug Combinations | Adenocarcinoma - mortality | Immunohistochemistry | Cancer patients | Care and treatment | Chemotherapy | Patient outcomes | Analysis | Cytogenetics | Stomach cancer | Formaldehyde | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 99 - 108
Journal Article
Cancer Science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1843 - 1850
This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second‐line... 
colorectal cancer | RAS mutation | panitumumab | liquid biopsy | Bevacizumab | 1ST-LINE TREATMENT | LEUCOVORIN | MULTICENTER | DETERMINANTS | PHASE-III | ACQUIRED-RESISTANCE | FLUOROURACIL | TRIAL | CETUXIMAB | ONCOLOGY | 2ND-LINE TREATMENT | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Biomarkers, Tumor | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Proto-Oncogene Proteins B-raf | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Retreatment | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Alleles | Aged | Mutation | Antimitotic agents | Chemotherapy | Endothelial growth factors | Analysis | Oncology, Experimental | Colorectal cancer | Clinical trials | Metastasis | Research | Antineoplastic agents | Blood proteins | Cancer | Immunoassay | Colorectal carcinoma | Values | Oncology | Serum proteins | Cancer therapies | K-Ras protein | Metastases | Proteins | Oxaliplatin | Epidermal growth factor | Vascular endothelial growth factor | Deoxyribonucleic acid--DNA | Immunoglobulins | Survival | Patients | Studies | Irinotecan | Biomarkers | Ligands | Original
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article